The price of Syros Pharmaceuticals Inc (NASDAQ:SYRS) shares last traded on Wall Street fell -8.15% to $0.23.
SYRS stock price is now -76.80% away from the 50-day moving average and -93.37% away from the 200-day moving average. The market capitalization of the company currently stands at $5.67M.
With the price target enhanced from $11 to $15, H.C. Wainwright Upgraded its rating from Neutral to Buy for Syros Pharmaceuticals Inc (NASDAQ: SYRS). On September 22, 2020, Alliance Global Partners recently initiated its ‘Buy’ rating on the stock quoting a target price of $18, while ‘Wedbush’ rates the stock as ‘Neutral’
In other news, AKKARAJU SRINIVAS, Director bought 9,333 shares of the company’s stock on Dec 30 ’24. The stock was bought for $2,306 at an average price of $0.25. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 27 ’24, Affiliate Flagship Pioneering Fund VII, bought 1,331,624 shares of the business’s stock. A total of $279,641 was incurred on buying the stock at an average price of $0.21. A total of 35.03% of the company’s stock is owned by insiders.
During the past 12 months, Syros Pharmaceuticals Inc has had a low of $0.18 and a high of $8.17. The fifty day moving average price for SYRS is $0.99046 and a two-hundred day moving average price translates $3.464065 for the stock.
The latest earnings results from Syros Pharmaceuticals Inc (NASDAQ: SYRS) was released for 2024-09-30. The net profit margin was -25340.67% and return on equity was -776.96% for SYRS.
